koryu

crispr crispr

Long
koryu Aktualisiert   
NASDAQ:EDIT   Editas Medicine, Inc.
15
Follow up idea, see related idea

After 5 wave impulse down and two month accumulation phase below IPO level sideways,
expect trend reversal into bull market, the downtrend channel got broken and tested on weekly timeframe.
The first human got crispered in china. USA will follow in 2017, I speculate on public awareness and solid growth, maybe hype.

In case of bull market, we got the possible pitchfork
Kommentar:
and back above IPO!!! i love it <3
Kommentar:
look for rsi breakout into new highs, consolidation above 18$ would confirm reversal.

Kommentar:
Wyckoff scenario
Kommentar:
wyckoff playing out nicely, can buy on dips for reaccumulation 16-17$ range
trailing stop below pitchfork, this stock keeps giving for weeks now with great volatility
Kommentar:
made a little indicator to compare EDIT price with the BTK biotech index
At ipo the indicator is 0, values below 0 indicates that EDIT is undervalued compared to biotech index, values over 0 indicates EDIT is overvalued compared to biotech index. Also showing the MA20 of this line (black).

Kommentar:
Kommentar:
crispr again in the news after
Kommentar:
crispr again on all news sites after National Academy of Sciences releases Report "Human Genome Editing: Science, Ethics, and Governance"
Kommentar:
CRISPR patent goes to Broad Institute of Cambridge -> EDIT www.technologyreview...-to-broad-institute/
Kommentar:
pitchfork still intact!

wyckoff scenario also playing out as expected :-)

Kommentar:
Editas Medicine announces that its offering of 4M shares priced at $22.50 per share.
seekingalpha.com/new...-prices-90m-offering

resistance 0.5 fib keylevel at 28.20
Support 20.00-22.50
Kommentar:
doubled my position here
Kommentar:
this should be a bear trap, new chart on linear scale

Haftungsausschluss

Die Informationen und Veröffentlichungen sind nicht als Finanz-, Anlage-, Handels- oder andere Arten von Ratschlägen oder Empfehlungen gedacht, die von TradingView bereitgestellt oder gebilligt werden, und stellen diese nicht dar. Lesen Sie mehr in den Nutzungsbedingungen.